- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00510627
Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases (Prometheus)
A Prospective, Randomized, Active-Control, Multi-Center Study Assessing Overall Survival Using Chemotherapy With or Without Impedance-Based Radiofrequency Ablation for Subjects With Colorectal Cancer and Incurable Metastatic Liver Disease, Failing at Least First-Line Chemotherapy
Study Overview
Status
Intervention / Treatment
Detailed Description
The American Cancer Society has estimated that colorectal cancer is the second leading cause of cancer related deaths, with 106,370 new cases diagnosed in 2004. Due to the unique nature of the hepatic circulatory system, with preferential portal venous drainage of the gastrointestinal tract, the liver is the most common site for metastatic tumor growth from a colorectal carcinoma. It is estimated that approximately 20% of patients diagnosed with colorectal cancer will present with liver involvement at the time of diagnosis, and 50% of patients will manifest metastatic involvement of the liver following resection of the primary colorectal cancer. Over one half of patients who die of colorectal cancer have liver metastases at autopsy.
The current "gold standard" in the treatment of isolated metastatic liver disease is curative hepatic resection. Only within the last 20 years has surgical resection become a viable option, as in the past it was considered unjustified due to high morbidity and mortality rates. The primary drawback to hepatic resection is the sheer number of patients for whom it is contraindicated. Only 10-20% of patients liver metastases are candidates for surgical resection, owing to factors such as tumor locations, size, extent of disease, and other medical co-morbidities.
Historically, in cases where hepatic resection was contraindicated, systemic chemotherapy was the only alternative treatment. In the last several years an increasing number of hepatic directed therapies have become available such as hepatic artery ligation, radiation, hepatic artery infusion of chemotherapy, chemoembolization, and mechanical ablation of the tumor(s).
One mechanical method of ablation involves the use of radiofrequency thermal technology, also called radiofrequency ablation (RFA). The RFA procedure involves inserting an RF electrode into the center of a hepatic tumor mass under ultrasonic or CT guidance. Radiofrequency energy is then applied through the electrode, causing a thermal injury to the surrounding tumor tissue. Currently there are two basic designs for monitoring inter-procedural progress during RFA; temperature monitoring of set points within the target tissue with thermocouples, or assessing the system-wide impedance of tissue adjacent to the deployed electrode tines. Radiofrequency ablation systems are comprised of three components: a radiofrequency generator, an active electrode, and dispersive electrodes.
To date no prospective multi-center trials have been completed which would conclusively demonstrate whether RFA is an effective adjunct to systemic chemotherapy with respect to advantages in median overall survival compared with chemotherapy alone. The primary objective of this trial is to determine overall survival for subjects with colorectal cancer and incurable metastatic liver disease who fail at least first line chemotherapy and are treated with radiofrequency ablation plus additional chemotherapy, compared to subjects receiving additional chemotherapy only.
Study Type
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10016
- New York University
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- The Cleveland Clinic Foundation
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
All subjects must meet the following criteria:
- Subject must have incurable metastatic colorectal cancer with metastatic disease to the liver
- Subject must have extrahepatic metastatic disease, as confirmed by radiographic evidence or surgical/other documentation that cannot be treated by surgery or image guided therapy to an endpoint of no evidence of residual disease by imaging criteria
- Subject has received and, in the opinion of the treating physician, progressed through at least one prior chemotherapy regimen for metastatic disease, or has developed recurrent disease on or within 6 months of completing adjuvant therapy
- At least 50% of the total tumor burden is in the liver, as determined by the treating investigator, and prior to any study specified intervention (resection or ablation).
- Subject must have no more than 10 hepatic tumors remaining after surgical resection, with no tumor exhibiting a unidimensional size greater than 5cm
- Subject is medically eligible to receive RFA, as determined by the treating investigator
- Subject is naïve to, and medically eligible (as defined by the treating investigator) to receive, at least one of the following:
- an oxaliplatin containing regimen
- an irinotecan containing regimen
- an anti-EGFR monoclonal antibody-containing regimen (subject must be naïve to both cetuximab and panitumumab)
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1
- Age > 18 years
- Subject life expectancy > 3 months
- International Normalized Ratio (INR) < 2.0
- Platelets > 100 x103/mm3
- Total Bilirubin <1.5mg/dl
- Creatinine level < 2.0 mg/dl
- Must sign an Informed Consent form
Exclusion Criteria:
All subjects who meet any of the following criteria will not be enrolled into the study:
- Subjects's extrahepatic disease is amenable to curative surgical or image guided therapy
- Subject has known brain metastases
- Uncorrectable coagulopathy
- Subject is pregnant, nursing, or wishes to become pregnant during the study
- Other serious medical condition(s) (e.g. uncontrolled infection, uncontrolled cardiac disease) that, in the opinion of the treating investigator, would preclude study treatment or impact survival.
- Current or planned treatment with any experimental chemotherapy or biological agents
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A
Radiofrequency ablation in conjunction with chemotherapy
|
The RF3000 radiofrequency generator has the capacity to deliver 200 watts of alternating current to the needle electrode for the coagulation necrosis of soft tissue.
Other Names:
|
Active Comparator: B
Standard of care chemotherapy regimen
|
Standard of care chemotherapy regimen
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate Overall Survival in subjects receiving chemotherapy + RFA compared to chemotherapy alone.
Time Frame: Study duration
|
Study duration
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate any unanticipated adverse device effects.
Time Frame: Two years
|
Two years
|
To determine if there are differences in the incidence or severity of adverse events in the RFA + chemotherapy arm compared to the chemotherapy only arm.
Time Frame: Study duration
|
Study duration
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: William Jacqmein, Boston Scientific Corporation
Publications and helpful links
General Publications
- Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004 Jan 15;22(2):229-37. doi: 10.1200/JCO.2004.05.113. Epub 2003 Dec 2.
- Choti MA, Bulkley GB. Management of hepatic metastases. Liver Transpl Surg. 1999 Jan;5(1):65-80. doi: 10.1002/lt.500050113.
- Chapter 49, Colon, Rectal, and Anal Cancers. PART VI: THE CARE OF INDIVIDUALS WITH SPECIFIC CANCERS; pp: 1156-1214
- Cromheecke M, de Jong KP, Hoekstra HJ. Current treatment for colorectal cancer metastatic to the liver. Eur J Surg Oncol. 1999 Oct;25(5):451-63. doi: 10.1053/ejso.1999.0679.
- Kemeny NE, Atiq OT. Non-surgical treatment for liver metastases. Baillieres Best Pract Res Clin Gastroenterol. 1999 Dec;13(4):593-610. doi: 10.1053/bega.1999.0050.
- Fong Y. Surgical therapy of hepatic colorectal metastasis. CA Cancer J Clin. 1999 Jul-Aug;49(4):231-55. doi: 10.3322/canjclin.49.4.231.
- Bowles BJ, Machi J, Limm WM, Severino R, Oishi AJ, Furumoto NL, Wong LL, Oishi RH. Safety and efficacy of radiofrequency thermal ablation in advanced liver tumors. Arch Surg. 2001 Aug;136(8):864-9. doi: 10.1001/archsurg.136.8.864.
- Berber E, Pelley R, Siperstein AE. Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study. J Clin Oncol. 2005 Mar 1;23(7):1358-64. doi: 10.1200/JCO.2005.12.039. Epub 2005 Jan 31.
- Yoon SS, Tanabe KK. Surgical treatment and other regional treatments for colorectal cancer liver metastases. Oncologist. 1999;4(3):197-208.
- DeMatteo RP, Fong Y, Blumgart LH. Surgical treatment of malignant liver tumours. Baillieres Best Pract Res Clin Gastroenterol. 1999 Dec;13(4):557-74. doi: 10.1053/bega.1999.0048.
- Curley SA, Vecchio R. New trends in the surgical treatment of colorectal cancer liver metastases. Tumori. 1998 May-Jun;84(3):281-8. doi: 10.1177/030089169808400301.
- Dodd GD 3rd, Soulen MC, Kane RA, Livraghi T, Lees WR, Yamashita Y, Gillams AR, Karahan OI, Rhim H. Minimally invasive treatment of malignant hepatic tumors: at the threshold of a major breakthrough. Radiographics. 2000 Jan-Feb;20(1):9-27. doi: 10.1148/radiographics.20.1.g00ja019.
- Poston GJ. Radiofrequency ablation of colorectal liver metastases: where are we really going? J Clin Oncol. 2005 Mar 1;23(7):1342-4. doi: 10.1200/JCO.2005.10.911. Epub 2005 Jan 31. No abstract available.
- Pawlik TM, Abdalla EK, Ellis LM, Vauthey JN, Curley SA. Debunking dogma: surgery for four or more colorectal liver metastases is justified. J Gastrointest Surg. 2006 Feb;10(2):240-8. doi: 10.1016/j.gassur.2005.07.027.
- Giantonio et. Al. High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200
- Talamonti MS, Tellez C, Benson AB 3rd. Local-regional therapy for metastatic liver tumors. Cancer Treat Res. 1998;98:172-99. Review.
Study record dates
Study Major Dates
Study Start
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Neoplasms
- Neoplasms by Site
- Digestive System Neoplasms
- Liver Diseases
- Neoplastic Processes
- Neoplasm Metastasis
- Liver Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Topoisomerase Inhibitors
- Topoisomerase I Inhibitors
- Oxaliplatin
- Irinotecan
Other Study ID Numbers
- ONC-PM-032006
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Neoplasm
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityFirst Affiliated Hospital, Sun Yat-Sen University; Second Affiliated Hospital...RecruitingSecondary Malignant Neoplasm of LiverChina
-
University of MinnesotaRecruitingHepatocellular Carcinoma | Secondary Malignant Neoplasm of LiverUnited States
-
Fuda Cancer Hospital, GuangzhouShenzhen Hank Bioengineering InstituteCompletedSecondary Malignant Neoplasm of LiverChina
-
Istituto Clinico HumanitasTerminatedSecondary Malignant Neoplasm of LiverItaly
-
University of MilanCompletedSecondary Malignant Neoplasm of LiverItaly
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Liver | Unresectable Solid NeoplasmUnited States, Canada
-
Medical University of GrazCompleted
-
Peking Union Medical College HospitalShanghai Junshi Bioscience Co., Ltd.RecruitingHepatobiliary Neoplasm | Liver Neoplasm | Biliary Tract NeoplasmsChina
-
University of ZurichUnknownLiver Diseases | Liver Neoplasms | Hepatectomy | Surgery | Secondary Malignant Neoplasm of Liver | Colon Cancer Liver Metastases | Malignant Neoplasm of Large Intestine Metastatic to LiverSwitzerland
-
Jules Bordet InstituteUniversity Hospital, GhentCompletedColorectal Neoplasm | Secondary Malignant Neoplasm of LiverBelgium
Clinical Trials on Radiofrequency Ablation (RFA)
-
Bing HuCompletedCholangiocarcinoma | Ampullary CarcinomaChina
-
Brno University HospitalCompleted
-
Sun Yat-sen UniversityUnknownHepatitis B | Hepatocellular CarcinomaChina
-
Guy's and St Thomas' NHS Foundation TrustUnknownBarrett EsophagusUnited Kingdom
-
King Chulalongkorn Memorial HospitalCompleted
-
Seattle Children's HospitalSuspendedNeoplasms, Benign | Neoplasms, MalignantUnited States
-
Rijnstate HospitalSt. Antonius Hospital; BovenIJ Hospital; OLVGCompletedGreater Saphenous Vein InjuryNetherlands
-
Benha UniversityBeni-Suef UniversityCompleted
-
Lyman Medical Research Foundation, Inc.Halyard HealthUnknownOsteoarthritis of the KneeUnited States
-
Johns Hopkins UniversityRecruitingChronic Pain | Neck Pain | Cervical Facet Joint PainUnited States